Physician profile
Stephen Mccall
NPI 1578975389
$1,090.17
in general payments reported to CMS, 2019-2025
16 companies · $880 in 2025
The $880 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2023: $57.77 · 2024: $17.84 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240.69 | 2025 | |
| Lilly USA, LLC | $199.43 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $112.71 | 2025 | Gemtesa |
| Stryker Corporation | $98.67 | 2019 | |
| Novo Nordisk INC | $76.90 | 2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $76.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.19 | 2025 | Jardiance |
| Noven Therapeutics, LLC | $38.10 | 2025 | Xelstrym, Secuado |
| Allergan, INC. | $35.68 | 2019 | |
| Glaxosmithkline, LLC. | $29.39 | 2025 | Trelegy Ellipta |
| Averitas Pharma INC. | $27.41 | 2025 | Qutenza |
| Phathom Pharmaceuticals, INC. | $26.49 | 2025 | Voquezna |
| Forte Bio-Pharma LLC | $18.73 | 2023 | Prolate, Nalocet |
| Otsuka America Pharmaceutical, INC. | $16.60 | 2025 | Rexulti |
| Dynavax Technologies Corporation | $15.66 | 2025 | Heplisav-B |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mccall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.